SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (38)2/13/1997 2:11:00 PM
From: Boyce Burge   of 4474
 
Richard, You must be keeping a close watch on S. Schreiber! He and Crabtree are creating the excitement factor for Ariad. This deacetylase is maybe the equivalent of a fine tuning knob on that hGH-producing "mouse with a rheostat".

I also noted in the NY Times the value of recent deals for Gene therapy companies. Novartis valued Systemix at $300 mm. Cell Genesys valued Somatix at $80 mm (Liz Silverman found this a canny acquisition).

CEGE has a Market cap of $132 mm, TGEN $90 mm, GMED $100 mm and ARIA $144 mm. Chiron and others have probably an equal "amount of gene therapy technology, so call the total technology value $2 billion today. Yet the FTC estimates the gene therapy market in 2010 at possibly $45 BILLION.

My back of the envelope estimates is that $2 billion at 40% for 12 or 13 years is about $50 billion. If we can be patient, there should be a substantial reward.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News